European Journal of Epidemiology

, Volume 25, Issue 1, pp 45–53

Nitric oxide and clustering of metabolic syndrome components in pediatrics



This study was performed to determine the risk factor pattern of the metabolic syndrome (MetS) in association with serum nitric oxide metabolites (NOx) in children and adolescents. The study included 851 children and adolescents, aged 4–19 years. The MetS was defined according to modified Adult treatment Panel III criteria. Cluster analysis was performed using principle components analysis with varimax orthogonal rotation to examine the risk factor pattern of the MetS. The prevalence of MetS was 10.8 and 10.0% in males and females, respectively. Age-and sex-adjusted odds ratio of having MetS was significantly higher in the upper quartile of NOx compared to the lower quartile (2.2, 95% CI: 1.1–4.7, p = 0.029). In the whole population, three factors were identified including blood pressure/obesity, lipid/obesity, and glucose/NOx. Stratifying for sex, again three factors were retained; however, in males NOx was loaded in two factors. In conclusion, serum NOx was associated and loaded with other MetS components in cluster analysis of metabolic risk factors.


Adolescent Child Metabolic syndrome Nitric oxide Obesity 



Adult Treatment Panel III


Blood pressure


Confidence interval


Cardiovascular disease


Diastolic blood pressure


Endothelial nitric oxide synthase


Fasting plasma glucose


High-density lipoprotein cholesterol


Inducible nitric oxide synthase


Metabolic syndrome


Monitoring of trends and determinants in cardiovascular disease


Messenger ribonucleic acid


Measure of sampling adequacy


Nitric oxide


Nitric oxide metabolites


Systolic blood pressure


Total cholesterol




Tehran Lipid and Glucose Study


Waist circumference


World Health Organization


Waist-to-hip ratio


  1. 1.
    Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol. 2000;152:908–11. Discussion 12.CrossRefPubMedGoogle Scholar
  2. 2.
    Pladevall M, Singal B, Williams LK, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006;29:113–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Kohen-Avramoglu R, Theriault A, Adeli K. Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem. 2003;36:413–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Goodman E, Dolan LM, Morrison JA, Daniels SR. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation. 2005;111:1970–7.CrossRefPubMedGoogle Scholar
  5. 5.
    De Ferranti SD, Osganian SK. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diabetes Vasc Dis Res. 2007;4:285–96.CrossRefGoogle Scholar
  6. 6.
    Sen Y, Kandemir N, Alikasifoglu A, Gonc N, Ozon A. Prevalence and risk factors of metabolic syndrome in obese children and adolescents: the role of the severity of obesity. Eur J Pediatr. 2008;167:1183–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F. High prevalence of the metabolic syndrome in Iranian adolescents. Obesity (Silver Spring). 2006;14:377–82.CrossRefGoogle Scholar
  8. 8.
    Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract. 2003;61:29–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Azizi F, Mirmiran P, Sherafat-Kazemzadeh R. Pediatric obesity: an impending catastrophe. Arch Iran Med. 2008;11:242–5.PubMedGoogle Scholar
  10. 10.
    Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics. 2007;120:340–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Bao W, Srinivasan SR, Wattigney WA, Berenson GS. Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study. Arch Intern Med. 1994;154:1842–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290:2271–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am J Epidemiol. 1991;133:884–99.PubMedGoogle Scholar
  14. 14.
    Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol In adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRefGoogle Scholar
  15. 15.
    Hanley AJ, Festa A, D’Agostino RB Jr, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004;53:1773–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;152:897–907.CrossRefPubMedGoogle Scholar
  17. 17.
    Reimann M, Schutte AE, Malan L, Huisman HW, Malan NT. Hyperuricaemia is an independent factor for the metabolic syndrome in a sub-Saharan African population: a factor analysis. Atherosclerosis. 2008;197:638–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Yoon S, Moon J, Shin C, Kim E, Jo SA, Jo I. Smoking status-dependent association of the 27-bp repeat polymorphism in intron 4 of endothelial nitric oxide synthase gene with plasma nitric oxide concentrations. Clin Chim Acta. 2002;324:113–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Ueyama J, Kondo T, Imai R, et al. Association of serum NOx level with clustering of metabolic syndrome components in middle-aged and elderly general populations in Japan. Environ Health Prev Med. 2008;13:36–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Zahedi Asl S, Ghasemi A, Azizi F. Serum nitric oxide metabolites in subjects with metabolic syndrome. Clin Biochem. 2008;41:1342–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Choi JW. Enhanced nitric oxide production is closely associated with serum lipid concentrations in adolescents. Clin Chim Acta. 2004;347:151–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Gruber HJ, Mayer C, Mangge H, Fauler G, Grandits N, Wilders-Truschnig M. Obesity reduces the bioavailability of nitric oxide in juveniles. Int J Obes (Lond). 2008;32:826–31.CrossRefGoogle Scholar
  23. 23.
    Lo HC, Lin SC, Wang YM. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clin Biochem. 2004;37:666–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–904.CrossRefPubMedGoogle Scholar
  25. 25.
    Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001;7:1138–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Colasanti M, Suzuki H. The dual personality of NO. Trends Pharmacol Sci. 2000;21:249–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Dallaire P, Marette A. Obesity-linked insulin resistance: is nitric oxide the missing link? Can J Diabetes. 2004;28:59–66.Google Scholar
  28. 28.
    Azizi F, Rahmani M, Emami H, Madjid M. Tehran Lipid and Glucose Study: rationale and design. CVD Prev. 2000;3:242–7.Google Scholar
  29. 29.
    Azizi F, Rahmani M, Emami H, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002;47:408–26.PubMedGoogle Scholar
  30. 30.
    Ghasemi A, Zahedi Asl S, Mehrabi Y, Saadat N, Azizi F. Serum nitric oxide metabolite levels in a general healthy population: relation to sex and age. Life Sci. 2008;83:326–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Ford ES, Li C. Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? J Pediatr. 2008;152:160–4.CrossRefPubMedGoogle Scholar
  32. 32.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114: 555–76.Google Scholar
  33. 33.
    Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Bmj. 2000;320:1240–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Pallant J. SPSS survival manual, a step by step guide to data analysis using SPSS for windows. Sydney: McGraw Hill; 2007.Google Scholar
  35. 35.
    Field A. Discovering statistics using SPSS. London: SAGE publications Ltd; 2009.Google Scholar
  36. 36.
    Dixon JK. Explaratory factor analysis. In: Munro BH, editor. Statistical methods for health care research. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 321–50.Google Scholar
  37. 37.
    Lambert M, Paradis G, O’Loughlin J, Delvin EE, Hanley JA, Levy E. Insulin resistance syndrome in a representative sample of children and adolescents from Quebec, Canada. Int J Obes Relat Metab Disord. 2004;28:833–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Higashino H, Miya H, Mukai H, Miya Y. Serum nitric oxide metabolite (NOx) levels in hypertensive patients at rest: a comparison of age, gender, blood pressure and complications using normotensive controls. Clin Exp Pharmacol Physiol. 2007;34:725–31.CrossRefPubMedGoogle Scholar
  39. 39.
    Choi JW, Pai SH, Kim SK, Ito M, Park CS, Cha YN. Increases in nitric oxide concentrations correlate strongly with body fat in obese humans. Clin Chem. 2001;47:1106–9.PubMedGoogle Scholar
  40. 40.
    Ding Y, Vaziri ND, Coulson R, Kamanna VS, Roh DD. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab. 2000;279:E11–7.PubMedGoogle Scholar
  41. 41.
    Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest. 1997;100:290–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Kelishadi R, Ardalan G, Adeli K, et al. Factor analysis of cardiovascular risk clustering in pediatric metabolic syndrome: CASPIAN study. Ann Nutr Metab. 2007;51:208–15.CrossRefPubMedGoogle Scholar
  43. 43.
    Ghosh A. Factor analysis of risk variables associated with metabolic syndrome in Asian Indian adolescents. Am J Hum Biol. 2007;19:34–40.CrossRefPubMedGoogle Scholar
  44. 44.
    Li C, Ford ES. Is there a single underlying factor for the metabolic syndrome in adolescents? A confirmatory factor analysis. Diabetes Care. 2007;30:1556–61.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen W, Srinivasan SR, Elkasabany A, Berenson GS. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black–White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol. 1999;150:667–74.PubMedGoogle Scholar
  46. 46.
    Moreno LA, Pineda I, Rodriguez G, et al. Leptin and metabolic syndrome in obese and non-obese children. Horm Metab Res. 2002;34:394–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Tanaka S, Yashiro A, Nakashima Y, Nanri H, Ikeda M, Kuroiwa A. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol. 1997;20:361–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Curcelli EC, Muller SS, Novelli Filho JL. Beneficial effects of diclofenac therapy on serum lipids, oxidized low-density lipoprotein and antioxidant defenses in rats. Life Sci. 2008;82:892–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Osawa M, Hayashi T, Nomura H, et al. Nitric oxide (NO) is a new clinical biomarker of survival in the elderly patients and its efficacy might be nearly equal to albumin. Nitric Oxide. 2007;16:157–63.CrossRefPubMedGoogle Scholar
  50. 50.
    Himeno M, Ishibashi T, Nakano S, et al. A practical procedure for achieving a steady state of NOx concentration in plasma: with special reference to the NOx content of Japanese daily food. Tohoku J Exp Med. 2003;199:95–110.CrossRefPubMedGoogle Scholar
  51. 51.
    Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension. 1997;30:405–8.PubMedGoogle Scholar
  52. 52.
    Ordookhani A, Mirmiran P, Najafi R, Hedayati M, Azizi F. Congenital hypothyroidism in Iran. Indian J Pediatr. 2003;70:625–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Asghar Ghasemi
    • 1
  • Saleh Zahediasl
    • 1
  • Fereidoun Azizi
    • 1
  1. 1.Endocrine Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations